New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
Medico Remedies receives order worth US$ 1,781,000
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
The audit has been concluded with no major observations
Subscribe To Our Newsletter & Stay Updated
